Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Article
  • Open Access

16 December 2025

22 Pages

Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort Collaboration

,
,
,
,
,
,
,
,
…
1
CHIP—Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark
2
HIV Infection Unit, Hospital de la Santa Creu I Sant Pau, Sant Quintí, 89, 08025 Barcelona, Spain
3
Reial Acadèmia de Medicina de Catalunya, 08001 Barcelona, Spain
4
Swiss HIV Cohort Study (SHCS), Kantonsspital Baselland, University of Basel, 4101 Bruderholz, Switzerland
This article belongs to the Special Issue Cancers in Chronic HIV Infection

Simple Summary

While cancer is a leading cause of death in people with HIV, less is known about clinical outcomes after cancer. We aimed to assess outcomes after the five most common cancers in people with HIV (Kaposi’s sarcoma (KS); non-Hodgkin lymphoma (NHL); and lung, anal and prostate cancers) in two international HIV cohort collaborations (D:A:D and RESPOND). We assessed incidence rates and risk factors of mortality, cardiovascular disease, diabetes, another primary cancer and AIDS events individually and as a non-fatal composite clinical outcome (CCO). Amongst 2485 participants, those with lung cancer had the highest rates of mortality, CCO and diabetes, whilst those with KS had the lowest rates of mortality, CCO, diabetes and cardiovascular disease. Higher CD4 count consistently protected against post-cancer mortality and CCO. Modifiable lifestyle factors (smoking, low BMI and high comorbidity burden) increased the risk of CCO after NHL and KS. These results highlight the importance of personalized post-cancer clinical monitoring.

Abstract

Background/Objectives: Whilst cancer is a leading cause of death in people with HIV, less is known about clinical outcomes after cancer. Methods: Participants from the RESPOND and D:A:D cohorts with the five most common cancers (Kaposi’s sarcoma (KS); non-Hodgkin lymphoma (NHL); and lung, anal and prostate cancers) were followed from first cancer diagnosis after 2006/2012 [D:A:D/RESPOND] until death, final follow-up or administrative censoring (2016/2021). Incidence rates (IR) were calculated for post-cancer mortality; for non-fatal events (cardiovascular disease, diabetes, another primary cancer, AIDS events) individually and as a non-fatal composite clinical outcome (CCO). Predictors or mortality and CCO were assessed using Poisson regression with generalized estimating equations. Results: Amongst 2485 participants with cancer, mortality and CCO IRs were highest after lung cancer (445.4/1000 person years [95% CI 399.7, 494.9], 117.1 [94.3, 143.8], respectively) compared to other cancers and lowest after KS (21.3 [16.9, 26.6], 43.9 [37.5, 51.3]). The most common non-fatal outcomes were AIDS events after NHL and KS, diabetes after lung and prostate cancer and another primary cancer after anal cancer. Among people with NHL and anal cancer, a diagnosis in more recent years was associated with lower mortality risk. Increasing the time-updated CD4 count reduced mortality by 15–40% (per 100 cells/µL) after NHL and anal and lung cancers and reduced CCO risk by 17–28% after KS and NHL. Smoking, low BMI and multimorbidity increased CCO risks by two to three times after KS and NHL. Conclusions: Risk of post-cancer mortality and non-fatal outcomes varies by cancer type and risk profile, suggesting the need for personalized post-cancer clinical monitoring.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.